Immunogenicity == Immunogenicity was evaluated using data from BGBA317302 and BGBA317303. studies. Tislelizumab exhibited doseproportional pharmacokinetics, and there were no clinically meaningful differences in tislelizumab’s pharmacokinetic parameters at 200 mg once every 3 weeks between BGBA317001 (n= 12, 83% White patients) and BGBA317102 (n= 20, 100% Chinese patients); race was not a significant covariate. No clinically relevant exposureefficacy/safety relationships were observed in BGBA317302/303. Incidence of antidrug antibodies (ADAs) was similar between Asian and White patients. The presence of ADAs was not clinically relevant for tislelizumab’s pharmacokinetic properties, efficacy, or safety. There were no differences in tislelizumab’s pharmacokinetic or ADA characteristics between Asian and White patients with advanced cancer and no clinically relevant exposureefficacy/safety dependency or impact of immunogenicity on efficacy and safety. Data from the extensive clinical program Naftopidil 2HCl of tislelizumab support the use of tislelizumab across broad patient populations with relevant tumor types. Keywords:exposureresponse, immunogenicity, pharmacokinetics, race impact, tislelizumab == Summary. == == 1. Introduction == Programmed cell death protein1 (PD1) and programmed deathligand 1 (PDL1) are immune checkpoint proteins that play a key role in regulating antitumor activity [1]. Binding of PD1 to PDL1 negatively regulates Tcellmediated immune responses, resulting in immune evasion and Tcell exhaustion [2]. AntiPD1 and antiPDL1 monoclonal antibodies have been used successfully to treat a broad range of advanced solid tumors both as monotherapy or in combination with other treatments (e.g., other immunotherapies and chemotherapies) [2]. However, multiple Naftopidil 2HCl mechanisms of resistance to PD1/PDL1 pathway blockade exist, including antibody clearance (CL) via antibodydependent cellular Rabbit Polyclonal to FSHR phagocytosis (ADCP) through macrophage Fc gamma receptor (FcR) binding [1,3]. Tislelizumab (BGBA317), a humanized immunoglobulin G4 monoclonal antibody Naftopidil 2HCl that targets and binds to PD1 with high affinity and specificity [3], was engineered to minimize FcR1 binding on macrophages. This limits ADCP, which has been shown to compromise the antitumor activity of other antiPD1 monoclonal antibodies through activation of antibodydependent, macrophagemediated killing of T effector cells [3]. Tislelizumab is currently being investigated for the treatment of solid tumors and hematologic cancers as a monotherapy and combination therapy. After demonstrating robust antitumor efficacy and a tolerable safety Naftopidil 2HCl profile in patients with advanced tumors, tislelizumab received National Medical Products Administration approval for 13 indications in China, as well as approvals in Europe, the United States, Australia, Brazil, Switzerland, the Republic of Korea, Singapore, Thailand, Israel, and the United Kingdom. With clinical trials of tislelizumab being conducted globally, it is important to understand whether tislelizumab has similar clinical effectiveness across different patient populations, especially those of different races. Using population pharmacokinetic (popPK) simulations of data from patients with advanced solid tumors or classical Hodgkin lymphoma (cHL), we previously demonstrated that tislelizumab dose adjustment is not required for specific patient populations [4,5]. In addition, there was no statistically significant correlation between the pharmacokinetic exposure of tislelizumab and objective response rate (ORR) or safety endpoints [5]. In this analysis, we provide an overview of the clinical pharmacology of tislelizumab, including pharmacokinetics, correlations with efficacy and safety, and immunogenicity properties, with a focus on patient race. == 2. Methods == Full details of the analysis dataset and characterization of the popPK modeling approach have previously been reported [4,5]. TableS1includes the study designs, patient populations, and analyses conducted [4]. All relevant institutional review boards/independent ethics committees reviewed the protocols and amendments and approved the studies, which were carried out in accordance with the International Conference on Harmonisation Good Clinical Practice Guideline, the principles of the Declaration of Helsinki, and local laws and regulations. == 2.1. Noncompartmental Analysis == A noncompartmental pharmacokinetic analysis was conducted to evaluate the pharmacokinetic profile of patients who were enrolled in BGBA317001 (data cutoff date: August 26, 2020) and BGBA317102 (data cutoff Naftopidil 2HCl date: May 31, 2020). == 2.2. Population Pharmacokinetic Model Simulations == Using pooled data from 12.
